Skip to main content
. Author manuscript; available in PMC: 2023 May 10.
Published in final edited form as: J Hepatol. 2022 Nov 12;78(2):247–259. doi: 10.1016/j.jhep.2022.10.034

Fig. 5. Sensitivity analysis assessing the impact of disease prevalence on PPV and NPV.

Fig. 5.

For Agile 4, the prevalence of cirrhosis was varied from 0.02 to 0.25 for (A) the cut-off of 0.251 (sensitivity = 0.79, specificity = 0.83) and (B) the cut-off of 0.565 (sensitivity = 0.53, specificity = 0.96) to evaluate their impact on NPV and PPV. For Agile 3+, the prevalence of advanced fibrosis was varied from 0.05 to 0.55 for (C) the cut-off of 0.451 (sensitivity = 0.87, specificity = 0.76) and (D) the cut-off of 0.679 (sensitivity = 0.69, specificity = 0.91). NPV, negative predictive value; PPV, positive predictive value.